LY-266,097

LY-266,097

LY-266,097

Chemical compound

LY-266,097 is a research ligand which acts as a potent and selective antagonist for the 5-HT2B receptor, with more than 100x selectivity over the related 5-HT2A and 5-HT2C receptor subtypes.[1] It has been used to study the role of the 5-HT2B receptor in modulating dopamine release in the brain,[2][3] as well as its involvement in other processes such as allodynia.[4]

Quick Facts Legal status, Identifiers ...

References

  1. [1]
    Krempaska K, Barnowski S, Gavini J, Hobi N, Ebener S, Simillion C, et al. (January 2020). "Azithromycin has enhanced effects on lung fibroblasts from idiopathic pulmonary fibrosis (IPF) patients compared to controls [corrected]". Respiratory Research. 21 (1): 25. doi:10.1186/s12931-020-1275-8. PMC 6964061. PMID 31941499.
  2. [2]
    Auclair AL, Cathala A, Sarrazin F, Depoortère R, Piazza PV, Newman-Tancredi A, Spampinato U (September 2010). "The central serotonin 2B receptor: a new pharmacological target to modulate the mesoaccumbens dopaminergic pathway activity". Journal of Neurochemistry. 114 (5): 1323–1332. doi:10.1111/j.1471-4159.2010.06848.x. PMID 20534001. S2CID 45607832.
  3. [3]
    Devroye C, Cathala A, Haddjeri N, Rovera R, Vallée M, Drago F, et al. (October 2016). "Differential control of dopamine ascending pathways by serotonin2B receptor antagonists: New opportunities for the treatment of schizophrenia". Neuropharmacology. 109: 59–68. doi:10.1016/j.neuropharm.2016.05.024. PMID 27260325. S2CID 46847094.
  4. [4]
    Pineda-Farias JB, Velázquez-Lagunas I, Barragán-Iglesias P, Cervantes-Durán C, Granados-Soto V (February 2015). "5-HT2B Receptor Antagonists Reduce Nerve Injury-Induced Tactile Allodynia and Expression of 5-HT2B Receptors". Drug Development Research. 76 (1): 31–39. doi:10.1002/ddr.21238. PMID 25620128. S2CID 26049138.
Stub icon

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.
Share this article:

This article uses material from the Wikipedia article LY-266,097, and is written by contributors. Text is available under a CC BY-SA 4.0 International License; additional terms may apply. Images, videos and audio are available under their respective licenses.